% alzhub.org library filter
% Source: https://alzhub.org/research?score_min=67&design=trial
% 114 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{pascuallucas2025-41058018,
  author  = {Pascual-Lucas, M. and Lacosta, A. M. and Montañés, M. and Canudas, J. and Loscos, J. and Monleón, I. and Allué, J. A. and Sarasa, L. and others},
  title   = {{Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70776},
  pmid    = {41058018},
  url     = {https://doi.org/10.1002/alz.70776}
}

@article{asada2025-40302041,
  author  = {Asada, Takashi and Thanasopoulou, Angeliki and Delmar, Paul and Wojtowicz, Jakub and Smith, Janice and Yoshiyama, Yasumasa and Yokoi, Katsunori and Watanabe, Chigusa and others},
  title   = {{Japanese participant data from three gantenerumab trials in early Alzheimer's disease}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70192},
  pmid    = {40302041},
  url     = {https://doi.org/10.1002/alz.70192}
}

@article{salloway2025-40390253,
  author  = {Salloway, S. and Pain, A. and Lee, E. and Papka, M. and Ferguson, M. B. and Wang, H. and Hu, H. and Lu, M. and others},
  title   = {{TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70293},
  pmid    = {40390253},
  url     = {https://doi.org/10.1002/alz.70293}
}

@article{vijverberg2026-41930592,
  author  = {Vijverberg, Everard G B and Scharre, Douglas W and Woodward, Michael and Catalano, Susan and Hamby, Mary E and Grundman, Michael and Morgan, Roger E and Iaci, Jennifer and others},
  title   = {{Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's disease}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2026},
  doi     = {10.1177/13872877261437145},
  pmid    = {41930592},
  url     = {https://doi.org/10.1177/13872877261437145}
}

@article{salloway2014-24450891,
  author  = {Salloway, S. and Sperling, R. and Fox, N. C. and Blennow, K. and Klunk, W. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others},
  title   = {{Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease}},
  journal = {The New England journal of medicine},
  year    = {2014},
  doi     = {10.1056/nejmoa1304839},
  pmid    = {24450891},
  url     = {https://doi.org/10.1056/nejmoa1304839}
}

@article{holper2026-41980907,
  author  = {Holper, Sarah and Barnham, Kevin J and Churilov, Leonid and Yates, Paul and Brodtmann, Amy and Johns, Sally and Li, Qia-Xin and Bhalala, Oneil and others},
  title   = {{A phase 2, randomized, multicenter, double-blind, placebo-controlled trial of S-adenosyl methionine in participants with mild cognitive impairment or dementia due to Alzheimer's disease}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2026},
  doi     = {10.1002/alz.71381},
  pmid    = {41980907},
  url     = {https://doi.org/10.1002/alz.71381}
}

@article{burns2021-34146512,
  author  = {Burns, Daniel K and Alexander, Robert C and Welsh-Bohmer, Kathleen A and Culp, Meredith and Chiang, Carl and O'Neil, Janet and Evans, Rebecca M and Harrigan, Patrick and others},
  title   = {{Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial}},
  journal = {The Lancet. Neurology},
  year    = {2021},
  doi     = {10.1016/s1474-4422(21)00043-0},
  pmid    = {34146512},
  url     = {https://doi.org/10.1016/s1474-4422(21)00043-0}
}

@article{macfarlane2025-39800452,
  author  = {Macfarlane, S. and Grimmer, T. and Teo, K. and O'Brien, T. J. and Woodward, M. and Grunfeld, J. and Mander, A. and Brodtmann, A. and others},
  title   = {{Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2024.100016},
  pmid    = {39800452},
  url     = {https://doi.org/10.1016/j.tjpad.2024.100016}
}

@article{toda2024-39350371,
  author  = {Toda, Y. and Iwatsubo, T. and Nakamura, Y. and Matsuda, N. and Miyata, M. and Jin, M. and Chen, T. and Kuribayashi, K. and others},
  title   = {{Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2024},
  doi     = {10.14283/jpad.2024.106},
  pmid    = {39350371},
  url     = {https://doi.org/10.14283/jpad.2024.106}
}

@article{nisenbaum2023-36795603,
  author  = {Nisenbaum, Laura and Martone, Robert and Chen, Tianle and Rajagovindan, Rajasimhan and Dent, Gersham and Beaver, John and Rubel, Carrie and Racine, Annie and others},
  title   = {{CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2023},
  doi     = {10.1002/alz.12919},
  pmid    = {36795603},
  url     = {https://doi.org/10.1002/alz.12919}
}

@article{abdelhaleem2026-40435316,
  author  = {Abdel-Haleem, Alyaa M and Casavant, Ellen and Toth, Balazs and Teng, Edmond and Monteiro, Cecilia and Pandya, Nikhil J and Glock, Caspar and Hoogenraad, Casper C and others},
  title   = {{CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures}},
  journal = {Brain : a journal of neurology},
  year    = {2026},
  doi     = {10.1093/brain/awaf200},
  pmid    = {40435316},
  url     = {https://doi.org/10.1093/brain/awaf200}
}

@article{zimmer2025-40063015,
  author  = {Zimmer, J. A. and Ardayfio, P. and Wang, H. and Khanna, R. and Evans, C. D. and Lu, M. and Sparks, J. and Andersen, S. and Lauzon, S. and Nery, E. S. M. and others},
  title   = {{Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials}},
  journal = {JAMA Neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.0065},
  pmid    = {40063015},
  url     = {https://doi.org/10.1001/jamaneurol.2025.0065}
}

@article{salloway2022-34807243,
  author  = {Salloway, S. and Chalkias, S. and Barkhof, F. and Burkett, P. and Barakos, J. and Purcell, D. and Suhy, J. and Forrestal, F. and others},
  title   = {{Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2021.4161},
  pmid    = {34807243},
  url     = {https://doi.org/10.1001/jamaneurol.2021.4161}
}

@article{bateman2025-40120616,
  author  = {Bateman, Randall J and Li, Yan and McDade, Eric M and Llibre-Guerra, Jorge J and Clifford, David B and Atri, Alireza and Mills, Susan L and Santacruz, Anna M and others},
  title   = {{Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial}},
  journal = {The Lancet. Neurology},
  year    = {2025},
  doi     = {10.1016/s1474-4422(25)00024-9},
  pmid    = {40120616},
  url     = {https://doi.org/10.1016/s1474-4422(25)00024-9}
}

@article{perry2026-41689888,
  author  = {Perry, Richard and Kipps, Christopher and Martín, Maria Eugenia Soto and Bozzali, Marco and Logroscino, Giancarlo and Trafford, Sarah and Dhadda, Shobha and Kanekiyo, Michio and others},
  title   = {{Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2026},
  doi     = {10.1016/j.tjpad.2026.100507},
  pmid    = {41689888},
  url     = {https://doi.org/10.1016/j.tjpad.2026.100507}
}

@article{buddhaeberlein2022-35542991,
  author  = {Budd Haeberlein, S. and Aisen, P. S. and Barkhof, F. and Chalkias, S. and Chen, T. and Cohen, S. and Dent, G. and Hansson, O. and others},
  title   = {{Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2022},
  doi     = {10.14283/jpad.2022.30},
  pmid    = {35542991},
  url     = {https://doi.org/10.14283/jpad.2022.30}
}

@article{honig2018-29365294,
  author  = {Honig, L. S. and Vellas, B. and Woodward, M. and Boada, M. and Bullock, R. and Borrie, M. and Hager, K. and Andreasen, N. and others},
  title   = {{Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2018},
  doi     = {10.1056/nejmoa1705971},
  pmid    = {29365294},
  url     = {https://doi.org/10.1056/nejmoa1705971}
}

@article{florian2023-36730056,
  author  = {Florian, H. and Wang, D. and Arnold, S. E. and Boada, M. and Guo, Q. and Jin, Z. and Zheng, H. and Fisseha, N. and others},
  title   = {{Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study}},
  journal = {Brain : a journal of neurology},
  year    = {2023},
  doi     = {10.1093/brain/awad024},
  pmid    = {36730056},
  url     = {https://doi.org/10.1093/brain/awad024}
}

@article{costa2022-34942135,
  author  = {Costa, Alberto C S and Brandão, Ana C and Boada, Richard and Barrionuevo, Veridiana L and Taylor, Hudson G and Roth, Elizabeth and Stasko, Melissa R and Johnson, Mark W and others},
  title   = {{Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial}},
  journal = {The Lancet. Neurology},
  year    = {2022},
  doi     = {10.1016/s1474-4422(21)00369-0},
  pmid    = {34942135},
  url     = {https://doi.org/10.1016/s1474-4422(21)00369-0}
}

@article{cummings2026-c800c391,
  author  = {Cummings, J. L. and Atri, A. and Scheltens, P. and others},
  title   = {{Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (EVOKE and EVOKE+): two phase 3, randomised, placebo-controlled trials}},
  journal = {The Lancet},
  year    = {2026},
  doi     = {10.1016/s0140-6736(26)00459-9},
  pmid    = {41865758},
  url     = {https://doi.org/10.1016/s0140-6736(26)00459-9}
}

@article{turner2015-26362286,
  author  = {Turner, R. S. and Thomas, R. G. and Craft, S. and van Dyck, C. H. and Mintzer, J. and Reynolds, B. A. and Brewer, J. B. and Rissman, R. A. and others},
  title   = {{A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease}},
  journal = {Neurology},
  year    = {2015},
  doi     = {10.1212/wnl.0000000000002035},
  pmid    = {26362286},
  url     = {https://doi.org/10.1212/wnl.0000000000002035}
}

@article{ostrowitzki2022-36121669,
  author  = {Ostrowitzki, S. and Bittner, T. and Sink, K. M. and Mackey, H. and Rabe, C. and Honig, L. S. and Cassetta, E. and Woodward, M. and others},
  title   = {{Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.2909},
  pmid    = {36121669},
  url     = {https://doi.org/10.1001/jamaneurol.2022.2909}
}

@article{bateman2023-37966285,
  author  = {Bateman, R. J. and Smith, J. and Donohue, M. C. and Delmar, P. and Abbas, R. and Salloway, S. and Wojtowicz, J. and Blennow, K. and others},
  title   = {{Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2023},
  doi     = {10.1056/nejmoa2304430},
  pmid    = {37966285},
  url     = {https://doi.org/10.1056/nejmoa2304430}
}

@article{swanson2021-33865446,
  author  = {Swanson, C. J. and Zhang, Y. and Dhadda, S. and Wang, J. and Kaplow, J. and Lai, R. Y. K. and Lannfelt, L. and Bradley, H. and others},
  title   = {{A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody}},
  journal = {Alzheimer's research \& therapy},
  year    = {2021},
  doi     = {10.1186/s13195-021-00813-8},
  pmid    = {33865446},
  url     = {https://doi.org/10.1186/s13195-021-00813-8}
}

@article{cummings2025-39780249,
  author  = {Cummings, J. L. and Atri, A. and Feldman, H. H. and Hansson, O. and Sano, M. and Knop, F. K. and Johannsen, P. and León, T. and others},
  title   = {{evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2025},
  doi     = {10.1186/s13195-024-01666-7},
  pmid    = {39780249},
  url     = {https://doi.org/10.1186/s13195-024-01666-7}
}

@article{mcdade2022-36544184,
  author  = {McDade, E. and Cummings, J. L. and Dhadda, S. and Swanson, C. J. and Reyderman, L. and Kanekiyo, M. and Koyama, A. and Irizarry, M. and others},
  title   = {{Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study}},
  journal = {Alzheimer's research \& therapy},
  year    = {2022},
  doi     = {10.1186/s13195-022-01124-2},
  pmid    = {36544184},
  url     = {https://doi.org/10.1186/s13195-022-01124-2}
}

@article{greeley2025-40912996,
  author  = {Greeley, David and Nash, Marshall and Herskowitz, Brad and Kim, Fred and Rock, James and Prins, Neils and Kim, SangYun and Xi, Tianyang and others},
  title   = {{A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2025.100337},
  pmid    = {40912996},
  url     = {https://doi.org/10.1016/j.tjpad.2025.100337}
}

@article{green2009-20009055,
  author  = {Green, R. C. and Schneider, L. S. and Amato, D. A. and Beelen, A. P. and Wilcock, G. and Swabb, E. A. and Zavitz, K. H. and {Tarenflurbil Phase 3 Study Group}},
  title   = {{Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial}},
  journal = {JAMA},
  year    = {2009},
  doi     = {10.1001/jama.2009.1866},
  pmid    = {20009055},
  url     = {https://doi.org/10.1001/jama.2009.1866}
}

@article{vandyck2023-36449413,
  author  = {van Dyck, C. H. and Swanson, C. J. and Aisen, P. and Bateman, R. J. and Chen, C. and Gee, M. and Kanekiyo, M. and Li, D. and others},
  title   = {{Lecanemab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2023},
  doi     = {10.1056/nejmoa2212948},
  pmid    = {36449413},
  url     = {https://doi.org/10.1056/nejmoa2212948}
}

@article{wilkinson2014-25297016,
  author  = {Wilkinson, David and Windfeld, Kristian and Colding-Jørgensen, Eskild},
  title   = {{Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial}},
  journal = {The Lancet. Neurology},
  year    = {2014},
  doi     = {10.1016/s1474-4422(14)70198-x},
  pmid    = {25297016},
  url     = {https://doi.org/10.1016/s1474-4422(14)70198-x}
}

@article{vandenberghe2016-27176461,
  author  = {Vandenberghe, R. and Rinne, J. O. and Boada, M. and Katayama, S. and Scheltens, P. and Vellas, B. and Tuchman, M. and Gass, A. and others},
  title   = {{Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials}},
  journal = {Alzheimer's research \& therapy},
  year    = {2016},
  doi     = {10.1186/s13195-016-0189-7},
  pmid    = {27176461},
  url     = {https://doi.org/10.1186/s13195-016-0189-7}
}

@article{mintun2021-33720637,
  author  = {Mintun, M. A. and Lo, A. C. and Duggan Evans, C. and Wessels, A. M. and Ardayfio, P. A. and Andersen, S. W. and Shcherbinin, S. and Sparks, J. and others},
  title   = {{Donanemab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2021},
  doi     = {10.1056/nejmoa2100708},
  pmid    = {33720637},
  url     = {https://doi.org/10.1056/nejmoa2100708}
}

@article{sperling2023-37458272,
  author  = {Sperling, R. A. and Donohue, M. C. and Raman, R. and Rafii, M. S. and Johnson, K. and Masters, C. L. and van Dyck, C. H. and Iwatsubo, T. and others},
  title   = {{Trial of Solanezumab in Preclinical Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2023},
  doi     = {10.1056/nejmoa2305032},
  pmid    = {37458272},
  url     = {https://doi.org/10.1056/nejmoa2305032}
}

@article{cury2025-41160460,
  author  = {Cury, Rafael de Morais and da Silva, Taynara and Cezar-Dos-Santos, Fernando and Fakih, Yasmin Rafaela Correia and Narvaez, Karlin Andrea Ramírez and Gouvea, Murilo Chaves and Espínola, Carlos and Ferreira, Charles Francisco and others},
  title   = {{A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2025},
  doi     = {10.1177/13872877251389608},
  pmid    = {41160460},
  url     = {https://doi.org/10.1177/13872877251389608}
}

@article{sauder2022-36414626,
  author  = {Sauder, Colin and Allen, Luke A and Baker, Elizabeth and Miller, Andrew C and Paul, Steven M and Brannan, Stephen K},
  title   = {{Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study}},
  journal = {Translational psychiatry},
  year    = {2022},
  doi     = {10.1038/s41398-022-02254-9},
  pmid    = {36414626},
  url     = {https://doi.org/10.1038/s41398-022-02254-9}
}

@article{koch2022-36281767,
  author  = {Koch, G. and Casula, E. P. and Bonnì, S. and Borghi, I. and Assogna, M. and Minei, M. and Pellicciari, M. C. and Motta, C. and others},
  title   = {{Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial}},
  journal = {Brain : a journal of neurology},
  year    = {2022},
  doi     = {10.1093/brain/awac285},
  pmid    = {36281767},
  url     = {https://doi.org/10.1093/brain/awac285}
}

@article{chan2022-36454969,
  author  = {Chan, D. and Suk, H. J. and Jackson, B. L. and Milman, N. P. and Stark, D. and Klerman, E. B. and Kitchener, E. and Fernandez Avalos, V. S. and others},
  title   = {{Gamma frequency sensory stimulation in mild probable Alzheimer's dementia patients: Results of feasibility and pilot studies}},
  journal = {PloS one},
  year    = {2022},
  doi     = {10.1371/journal.pone.0278412},
  pmid    = {36454969},
  url     = {https://doi.org/10.1371/journal.pone.0278412}
}

@article{edison2025-41326666,
  author  = {Edison, P. and Femminella, G. D. and Ritchie, C. and Nowell, J. and Holmes, C. and Walker, Z. and Ridha, B. and Raza, S. and Livingston, N. R. and Frangou, E. and others},
  title   = {{Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial}},
  journal = {Nature Medicine},
  year    = {2025},
  doi     = {10.1038/s41591-025-04106-7},
  pmid    = {41326666},
  url     = {https://doi.org/10.1038/s41591-025-04106-7}
}

@article{honig2024-38730496,
  author  = {Honig, L. S. and Sabbagh, M. N. and van Dyck, C. H. and Sperling, R. A. and Hersch, S. and Matta, A. and Giorgi, L. and Gee, M. and others},
  title   = {{Updated safety results from phase 3 lecanemab study in early Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2024},
  doi     = {10.1186/s13195-024-01441-8},
  pmid    = {38730496},
  url     = {https://doi.org/10.1186/s13195-024-01441-8}
}

@article{wessels2020-31764959,
  author  = {Wessels, A. M. and Tariot, P. N. and Zimmer, J. A. and Selzler, K. J. and Bragg, S. M. and Andersen, S. W. and Landry, J. and Krull, J. H. and others},
  title   = {{Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials}},
  journal = {JAMA neurology},
  year    = {2020},
  doi     = {10.1001/jamaneurol.2019.3988},
  pmid    = {31764959},
  url     = {https://doi.org/10.1001/jamaneurol.2019.3988}
}

@article{teng2022-35696185,
  author  = {Teng, E. and Manser, P. T. and Pickthorn, K. and Brunstein, F. and Blendstrup, M. and Sanabria Bohorquez, S. and Wildsmith, K. R. and Toth, B. and others},
  title   = {{Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.1375},
  pmid    = {35696185},
  url     = {https://doi.org/10.1001/jamaneurol.2022.1375}
}

@article{henderson2016-26795874,
  author  = {Henderson, E. J. and Lord, SR. and Brodie, M. A. and Gaunt, D. M. and Lawrence, A. D. and Close, J. C. and Whone, A. L. and others},
  title   = {{Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial}},
  journal = {The Lancet. Neurology},
  year    = {2016},
  doi     = {10.1016/s1474-4422(15)00389-0},
  pmid    = {26795874},
  url     = {https://doi.org/10.1016/s1474-4422(15)00389-0}
}

@article{novak2017-27955995,
  author  = {Novak, P. and Schmidt, R. and Kontsekova, E. and Zilka, N. and Kovacech, B. and Skrabana, R. and Vince-Kazmerova, Z. and Katina, S. and others},
  title   = {{Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial}},
  journal = {The Lancet. Neurology},
  year    = {2017},
  doi     = {10.1016/s1474-4422(16)30331-3},
  pmid    = {27955995},
  url     = {https://doi.org/10.1016/s1474-4422(16)30331-3}
}

@article{koh2021-33771205,
  author  = {Koh, Seong-Ho and Kwon, Hyuk Sung and Choi, Seong Hye and Jeong, Jee Hyang and Na, Hae Ri and Lee, Chan Nyoung and Yang, YoungSoon and Lee, Ae Young and others},
  title   = {{Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial}},
  journal = {Alzheimer's research \& therapy},
  year    = {2021},
  doi     = {10.1186/s13195-021-00803-w},
  pmid    = {33771205},
  url     = {https://doi.org/10.1186/s13195-021-00803-w}
}

@article{craft2020-32568367,
  author  = {Craft, S. and Raman, R. and Chow, T. W. and Rafii, M. S. and Sun, C. K. and Rissman, R. A. and Donohue, M. C. and Brewer, J. B. and others},
  title   = {{Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2020},
  doi     = {10.1001/jamaneurol.2020.1840},
  pmid    = {32568367},
  url     = {https://doi.org/10.1001/jamaneurol.2020.1840}
}

@article{salloway2025-39556389,
  author  = {Salloway, S. and Wojtowicz, J. and Voyle, N. and Lane, C. A. and Klein, G. and Lyons, M. and Rossomanno, S. and Mazzo, F. and others},
  title   = {{Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease}},
  journal = {JAMA neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2024.3937},
  pmid    = {39556389},
  url     = {https://doi.org/10.1001/jamaneurol.2024.3937}
}

@article{salloway2018-30129411,
  author  = {Salloway, S. and Marshall, G. A. and Lu, M. and Brashear, H. R.},
  title   = {{Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study}},
  journal = {Current Alzheimer research},
  year    = {2018},
  doi     = {10.2174/1567205015666180821114813},
  pmid    = {30129411},
  url     = {https://doi.org/10.2174/1567205015666180821114813}
}

@article{neve2024-39177596,
  author  = {Neve, A. and Das, B. and Wojtowicz, J. and Huang, Z. and Bullain, S. and Watkin, M. and Lott, D. and Bittner, T. and others},
  title   = {{Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2024},
  doi     = {10.3233/jad-240221},
  pmid    = {39177596},
  url     = {https://doi.org/10.3233/jad-240221}
}

@article{holmes2004-15277611,
  author  = {Holmes, C. and Wilkinson, D. and Dean, C. and Vethanayagam, S. and Olivieri, S. and Langley, A. and Pandita-Gunawardena, N. D. and Hogg, F. and others},
  title   = {{The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease}},
  journal = {Neurology},
  year    = {2004},
  doi     = {10.1212/01.wnl.0000129990.32253.7b},
  pmid    = {15277611},
  url     = {https://doi.org/10.1212/01.wnl.0000129990.32253.7b}
}

@article{boess2024-38706270,
  author  = {Boess, F G and Scelsi, M A and Grimmer, T and Perry, R J and Tonietto, M and Klein, G and Hofmann, C and Salami, M and others},
  title   = {{At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2024},
  doi     = {10.14283/jpad.2024.60},
  pmid    = {38706270},
  url     = {https://doi.org/10.14283/jpad.2024.60}
}

@article{nordberg2009-19199870,
  author  = {Nordberg, Agneta and Darreh-Shori, Taher and Peskind, Elaine and Soininen, Hilkka and Mousavi, Malahat and Eagle, Gina and Lane, Roger},
  title   = {{Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients}},
  journal = {Current Alzheimer research},
  year    = {2009},
  doi     = {10.2174/156720509787313961},
  pmid    = {19199870},
  url     = {https://doi.org/10.2174/156720509787313961}
}

@article{wang2025-40172303,
  author  = {Wang, H. and Serap Monkul Nery, E. and Ardayfio, P. and Khanna, R. and Otero Svaldi, D. and Gueorguieva, I. and Shcherbinin, S. and Andersen, S. W. and Hauck, P. M. and Engle, S. E. and others},
  title   = {{Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70062},
  pmid    = {40172303},
  url     = {https://doi.org/10.1002/alz.70062}
}

@article{lu2025-41082199,
  author  = {Lu, M. and Kim, M. J. and Collins, E. C. and Shcherbinin, S. and Ellinwood, A. K. and Yokoi, Y. and Brooks, D. A. and Hansson, O. and others},
  title   = {{Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.3869},
  pmid    = {41082199},
  url     = {https://doi.org/10.1001/jamaneurol.2025.3869}
}

@article{shcherbinin2022-36094645,
  author  = {Shcherbinin, S. and Evans, C. D. and Lu, M. and Andersen, S. W. and Pontecorvo, M. J. and Willis, B. A. and Gueorguieva, I. and Hauck, P. M. and others},
  title   = {{Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.2793},
  pmid    = {36094645},
  url     = {https://doi.org/10.1001/jamaneurol.2022.2793}
}

@article{han2017-28587629,
  author  = {Han, J. W. and Son, K. L. and Byun, H. J. and Ko, J. W. and Kim, K. and Hong, J. W. and Kim, T. H. and Kim, K. W.},
  title   = {{Efficacy of the Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training (USMART) program among patients with mild cognitive impairment: a randomized controlled crossover trial}},
  journal = {Alzheimer's research \& therapy},
  year    = {2017},
  doi     = {10.1186/s13195-017-0264-8},
  pmid    = {28587629},
  url     = {https://doi.org/10.1186/s13195-017-0264-8}
}

@article{farlow2012-22672770,
  author  = {Farlow, M. and Arnold, S. E. and van Dyck, C. H. and Aisen, P. S. and Snider, B. J. and Porsteinsson, A. P. and Friedrich, S. and Dean, R. A. and others},
  title   = {{Safety and biomarker effects of solanezumab in patients with Alzheimer's disease}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2012},
  doi     = {10.1016/j.jalz.2011.09.224},
  pmid    = {22672770},
  url     = {https://doi.org/10.1016/j.jalz.2011.09.224}
}

@article{yaxley2016-27474375,
  author  = {Yaxley, J. W. and Coughlin, G. D. and Chambers, S. K. and Occhipinti, S. and Samaratunga, H. and Zajdlewicz, L. and Dunglison, N. and Carter, R. and others},
  title   = {{Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study}},
  journal = {Lancet (London, England)},
  year    = {2016},
  doi     = {10.1016/s0140-6736(16)30592-x},
  pmid    = {27474375},
  url     = {https://doi.org/10.1016/s0140-6736(16)30592-x}
}

@article{abushakra2017-29182706,
  author  = {Abushakra, S and Porsteinsson, A and Scheltens, P and Sadowsky, C and Vellas, B and Cummings, J and Gauthier, S and Hey, J A and others},
  title   = {{Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2017},
  doi     = {10.14283/jpad.2017.26},
  pmid    = {29182706},
  url     = {https://doi.org/10.14283/jpad.2017.26}
}

@article{relkin2017-28381506,
  author  = {Relkin, Norman R and Thomas, Ronald G and Rissman, Robert A and Brewer, James B and Rafii, Michael S and van Dyck, Christopher H and Jack, Clifford R and Sano, Mary and others},
  title   = {{A phase 3 trial of IV immunoglobulin for Alzheimer disease}},
  journal = {Neurology},
  year    = {2017},
  doi     = {10.1212/wnl.0000000000003904},
  pmid    = {28381506},
  url     = {https://doi.org/10.1212/wnl.0000000000003904}
}

@article{kadir2008-18300284,
  author  = {Kadir, A. and Andreasen, N. and Almkvist, O. and Wall, A. and Forsberg, A. and Engler, H. and Hagman, G. and Lärksäter, M. and others},
  title   = {{Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease}},
  journal = {Annals of neurology},
  year    = {2008},
  doi     = {10.1002/ana.21345},
  pmid    = {18300284},
  url     = {https://doi.org/10.1002/ana.21345}
}

@article{cummings2015-26393847,
  author  = {Cummings, J. L. and Lyketsos, C. G. and Peskind, E. R. and Porsteinsson, A. P. and Mintzer, J. E. and Scharre, D. W. and De La Gandara, J. E. and Agronin, M. and others},
  title   = {{Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2015},
  doi     = {10.1001/jama.2015.10214},
  pmid    = {26393847},
  url     = {https://doi.org/10.1001/jama.2015.10214}
}

@article{cohen2023-37874099,
  author  = {Cohen, S and van Dyck, C H and Gee, M and Doherty, T and Kanekiyo, M and Dhadda, S and Li, D and Hersch, S and others},
  title   = {{Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2023},
  doi     = {10.14283/jpad.2023.123},
  pmid    = {37874099},
  url     = {https://doi.org/10.14283/jpad.2023.123}
}

@article{vandyck2023-22dd8fce,
  author  = {van Dyck, C. H. and Swanson, C. J. and Aisen, P. and Bateman, R. J. and Chen, C. and Gee, M. and Kanekiyo, M. and Li, D. and Reyderman, L. and Cohen, S. and Froelich, L. and Katayama, S. and Sabbagh, M. and Vellas, B. and Watson, D. and Dhadda, S. and Irizarry, M. and Kramer, L. D. and Iwatsubo, T.},
  title   = {{Lecanemab in Early Alzheimer's Disease}},
  journal = {New England Journal of Medicine},
  year    = {2023},
  doi     = {10.1056/nejmoa2212948},
  pmid    = {36449413},
  url     = {https://doi.org/10.1056/nejmoa2212948}
}

@article{sims2023-9857475c,
  author  = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and Wang, H. and Monkul Nery, E. S. and Collins, E. C. and Solomon, P. and Salloway, S. and Apostolova, L. G. and Hansson, O. and Ritchie, C. and Brooks, D. A. and Mintun, M. and Skovronsky, D. M. and {TRAILBLAZER-ALZ 2 Investigators}},
  title   = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2023},
  doi     = {10.1001/jama.2023.13239},
  pmid    = {37459141},
  url     = {https://doi.org/10.1001/jama.2023.13239}
}

@article{rajji2025-40133524,
  author  = {Rajji, T. K. and Baksh, S. N. and Shade, D. M. and Ismail, Z. and Burhan, A. M. and Okhravi, H. R. and Padala, P. R. and Rosenberg, P. B. and Schneider, L. S. and Porsteinsson, A. P. and others},
  title   = {{Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial}},
  journal = {Nature Medicine},
  year    = {2025},
  doi     = {10.1038/s41591-025-03569-y},
  pmid    = {40133524},
  url     = {https://doi.org/10.1038/s41591-025-03569-y}
}

@article{salloway2009-19923550,
  author  = {Salloway, S. and Sperling, R. and Gilman, S. and Fox, N. C. and Blennow, K. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others},
  title   = {{A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2009},
  doi     = {10.1212/wnl.0b013e3181c67808},
  pmid    = {19923550},
  url     = {https://doi.org/10.1212/wnl.0b013e3181c67808}
}

@article{coric2012-22892585,
  author  = {Coric, V. and van Dyck, C. H. and Salloway, S. and Andreasen, N. and Brody, M. and Richter, R. W. and Soininen, H. and Thein, S. and others},
  title   = {{Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease}},
  journal = {Archives of neurology},
  year    = {2012},
  doi     = {10.1001/archneurol.2012.2194},
  pmid    = {22892585},
  url     = {https://doi.org/10.1001/archneurol.2012.2194}
}

@article{sims2023-37459141,
  author  = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and others},
  title   = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2023},
  doi     = {10.1001/jama.2023.13239},
  pmid    = {37459141},
  url     = {https://doi.org/10.1001/jama.2023.13239}
}

@article{cummings2018-29695589,
  author  = {Cummings, J. L. and Cohen, S. and van Dyck, C. H. and Brody, M. and Curtis, C. and Cho, W. and Ward, M. and Friesenhahn, M. and others},
  title   = {{ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2018},
  doi     = {10.1212/wnl.0000000000005550},
  pmid    = {29695589},
  url     = {https://doi.org/10.1212/wnl.0000000000005550}
}

@article{monteiro2023-37643887,
  author  = {Monteiro, C. and Toth, B. and Brunstein, F. and Bobbala, A. and Datta, S. and Ceniceros, R. and Sanabria Bohorquez, S. M. and Anania, V. G. and others},
  title   = {{Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet}},
  journal = {Neurology},
  year    = {2023},
  doi     = {10.1212/wnl.0000000000207663},
  pmid    = {37643887},
  url     = {https://doi.org/10.1212/wnl.0000000000207663}
}

@article{raskind2000-10881250,
  author  = {Raskind, M. A. and Peskind, E. R. and Wessel, T. and Yuan, W.},
  title   = {{Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group}},
  journal = {Neurology},
  year    = {2000},
  doi     = {10.1212/wnl.54.12.2261},
  pmid    = {10881250},
  url     = {https://doi.org/10.1212/wnl.54.12.2261}
}

@article{xiao2021-33731209,
  author  = {Xiao, S. and Chan, P. and Wang, T. and Hong, Z. and Wang, S. and Kuang, W. and He, J. and Pan, X. and others},
  title   = {{A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia}},
  journal = {Alzheimer's research \& therapy},
  year    = {2021},
  doi     = {10.1186/s13195-021-00795-7},
  pmid    = {33731209},
  url     = {https://doi.org/10.1186/s13195-021-00795-7}
}

@article{ornish2024-38849944,
  author  = {Ornish, D. and Madison, C. and Kivipelto, M. and Kemp, C. and McCulloch, C. E. and Galasko, D. and Artz, J. and Rentz, D. and others},
  title   = {{Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial}},
  journal = {Alzheimer's research \& therapy},
  year    = {2024},
  doi     = {10.1186/s13195-024-01482-z},
  pmid    = {38849944},
  url     = {https://doi.org/10.1186/s13195-024-01482-z}
}

@article{prins2021-34044875,
  author  = {Prins, N. D. and Harrison, J. E. and Chu, H. M. and Blackburn, K. and Alam, J. J. and Scheltens, P. and {REVERSE-SD Study Investigators}},
  title   = {{A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2021},
  doi     = {10.1186/s13195-021-00843-2},
  pmid    = {34044875},
  url     = {https://doi.org/10.1186/s13195-021-00843-2}
}

@article{richard2016-27288376,
  author  = {Richard, E. and Jongstra, S. and Soininen, H. and Brayne, C. and Moll van Charante, E. P. and Meiller, Y. and van der Groep, B. and Beishuizen, C. R. and others},
  title   = {{Healthy Ageing Through Internet Counselling in the Elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment}},
  journal = {BMJ open},
  year    = {2016},
  doi     = {10.1136/bmjopen-2015-010806},
  pmid    = {27288376},
  url     = {https://doi.org/10.1136/bmjopen-2015-010806}
}

@article{delnomdedieu2016-26925577,
  author  = {Delnomdedieu, M. and Duvvuri, S. and Li, D. J. and Atassi, N. and Lu, M. and Brashear, H. R. and Liu, E. and Ness, S. and others},
  title   = {{First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2016},
  doi     = {10.1186/s13195-016-0177-y},
  pmid    = {26925577},
  url     = {https://doi.org/10.1186/s13195-016-0177-y}
}

@article{gold2010-20733306,
  author  = {Gold, M. and Alderton, C. and Zvartau-Hind, M. and Egginton, S. and Saunders, A. M. and Irizarry, M. and Craft, S. and Landreth, G. and others},
  title   = {{Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study}},
  journal = {Dementia and geriatric cognitive disorders},
  year    = {2010},
  doi     = {10.1159/000318845},
  pmid    = {20733306},
  url     = {https://doi.org/10.1159/000318845}
}

@article{mummery2026-41787076,
  author  = {Mummery, C. J. and Mayorga, A. J. and Simmons, A. and Chow, T. W. and Burgess, B. and Nguyen, T. and Gao, J. and Budda, B. and Park, L. Q. and Gupta, R. and Li, C. and Shi, L. and others},
  title   = {{The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial}},
  journal = {Nature Medicine},
  year    = {2026},
  doi     = {10.1038/s41591-026-04273-1},
  pmid    = {41787076},
  url     = {https://doi.org/10.1038/s41591-026-04273-1}
}

@article{tsai2020-31710340,
  author  = {Tsai, R. M. and Miller, Z. and Koestler, M. and Rojas, J. C. and Ljubenkov, P. A. and Rosen, H. J. and Rabinovici, G. D. and Fagan, A. M. and others},
  title   = {{Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2020},
  doi     = {10.1001/jamaneurol.2019.3812},
  pmid    = {31710340},
  url     = {https://doi.org/10.1001/jamaneurol.2019.3812}
}

@article{baker2025-40271888,
  author  = {Baker, L. D. and Pa, J. A. and Katula, J. A. and Aslanyan, V. and Salmon, D. P. and Jacobs, D. M. and Chmelo, E. A. and Hodge, H. and Morrison, R. and Matthews, G. and others},
  title   = {{Effects of exercise on cognition and Alzheimer's biomarkers in a randomized controlled trial of adults with mild cognitive impairment: The EXERT study}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.14586},
  pmid    = {40271888},
  url     = {https://doi.org/10.1002/alz.14586}
}

@article{devanand2026-41405855,
  author  = {Devanand, D P and Wisniewski, Thomas and Razlighi, Qolamreza and Qian, Min and Wei, Renjie and Andrews, Howard F and Acosta, Edward P and Bell, Karen L and others},
  title   = {{Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2026},
  doi     = {10.1001/jama.2025.21738},
  pmid    = {41405855},
  url     = {https://doi.org/10.1001/jama.2025.21738}
}

@article{fleisher2024-38386949,
  author  = {Fleisher, A. S. and Munsie, L. M. and Perahia, D. G. S. and Andersen, S. W. and Higgins, I. A. and Hauck, P. M. and Lo, A. C. and Sims, JR. and others},
  title   = {{Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease}},
  journal = {Neurology},
  year    = {2024},
  doi     = {10.1212/wnl.0000000000208061},
  pmid    = {38386949},
  url     = {https://doi.org/10.1212/wnl.0000000000208061}
}

@article{ritchie2003-14676042,
  author  = {Ritchie, C. W. and Bush, A. I. and Mackinnon, A. and Macfarlane, S. and Mastwyk, M. and MacGregor, L. and Kiers, L. and Cherny, R. and others},
  title   = {{Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial}},
  journal = {Archives of neurology},
  year    = {2003},
  doi     = {10.1001/archneur.60.12.1685},
  pmid    = {14676042},
  url     = {https://doi.org/10.1001/archneur.60.12.1685}
}

@article{rogers1998-9588436,
  author  = {Rogers, S. L. and Doody, R. S. and Mohs, R. C. and Friedhoff, L. T.},
  title   = {{Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group}},
  journal = {Archives of internal medicine},
  year    = {1998},
  doi     = {10.1001/archinte.158.9.1021},
  pmid    = {9588436},
  url     = {https://doi.org/10.1001/archinte.158.9.1021}
}

@article{sha2019-30383097,
  author  = {Sha, S. J. and Deutsch, G. K. and Tian, L. and Richardson, K. and Coburn, M. and Gaudioso, J. L. and Marcal, T. and Solomon, E. and others},
  title   = {{Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2019},
  doi     = {10.1001/jamaneurol.2018.3288},
  pmid    = {30383097},
  url     = {https://doi.org/10.1001/jamaneurol.2018.3288}
}

@article{mori2012-22829268,
  author  = {Mori, E. and Ikeda, M. and Kosaka, K. and {Donepezil-DLB Study Investigators}},
  title   = {{Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial}},
  journal = {Annals of neurology},
  year    = {2012},
  doi     = {10.1002/ana.23557},
  pmid    = {22829268},
  url     = {https://doi.org/10.1002/ana.23557}
}

@article{cummings2026-41865758,
  author  = {Cummings, Jeffrey L and Atri, Alireza and Sano, Mary and Zetterberg, Henrik and Scheltens, Philip and Knop, Filip K and Johannsen, Peter and Wichmann, Christian Ahmad and others},
  title   = {{Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials}},
  journal = {The Lancet},
  year    = {2026},
  doi     = {10.1016/s0140-6736(26)00459-9},
  pmid    = {41865758},
  url     = {https://doi.org/10.1016/s0140-6736(26)00459-9}
}

@article{mummery2023-37095250,
  author  = {Mummery, C. J. and Börjesson-Hanson, A. and Blackburn, D. J. and Vijverberg, E. G. B. and De Deyn, P. P. and Ducharme, S. and Jonsson, M. and Schneider, A. and Rinne, J. O. and Ludolph, A. C. and Bodenschatz, R. and Kordasiewicz, H. and others},
  title   = {{Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial}},
  journal = {Nature Medicine},
  year    = {2023},
  doi     = {10.1038/s41591-023-02326-3},
  pmid    = {37095250},
  url     = {https://doi.org/10.1038/s41591-023-02326-3}
}

@article{singh2024-39432286,
  author  = {Singh, S. and Li, X. and Cocoros, N. M. and Antonelli, M. T. and Avula, R. and Crawford, S. L. and Dashevsky, I. and Fouayzi, H. and others},
  title   = {{High-Risk Medications in Persons Living With Dementia: A Randomized Clinical Trial}},
  journal = {JAMA internal medicine},
  year    = {2024},
  doi     = {10.1001/jamainternmed.2024.5632},
  pmid    = {39432286},
  url     = {https://doi.org/10.1001/jamainternmed.2024.5632}
}

@article{curtis2015-25622185,
  author  = {Curtis, C. and Gamez, J. E. and Singh, U. and Sadowsky, C. H. and Villena, T. and Sabbagh, M. N. and Beach, T. G. and Duara, R. and others},
  title   = {{Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density}},
  journal = {JAMA neurology},
  year    = {2015},
  doi     = {10.1001/jamaneurol.2014.4144},
  pmid    = {25622185},
  url     = {https://doi.org/10.1001/jamaneurol.2014.4144}
}

@article{long2024-39444037,
  author  = {Long, H. and Simmons, A. and Mayorga, A. and Burgess, B. and Nguyen, T. and Budda, B. and Rychkova, A. and Rhinn, H. and others},
  title   = {{Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2024},
  doi     = {10.1186/s13195-024-01599-1},
  pmid    = {39444037},
  url     = {https://doi.org/10.1186/s13195-024-01599-1}
}

@article{sevigny2024-38745011,
  author  = {Sevigny, J. and Uspenskaya, O. and Heckman, L. D. and Wong, L. C. and Hatch, D. A. and Tewari, A. and Vandenberghe, R. and Irwin, D. J. and others},
  title   = {{Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results}},
  journal = {Nature medicine},
  year    = {2024},
  doi     = {10.1038/s41591-024-02973-0},
  pmid    = {38745011},
  url     = {https://doi.org/10.1038/s41591-024-02973-0}
}

@article{morato2023-37012306,
  author  = {Morató, X. and Marquié, M. and Tartari, J. P. and Lafuente, A. and Abdelnour, C. and Alegret, M. and Jofresa, S. and Buendía, M. and others},
  title   = {{A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress}},
  journal = {Scientific reports},
  year    = {2023},
  doi     = {10.1038/s41598-023-32515-6},
  pmid    = {37012306},
  url     = {https://doi.org/10.1038/s41598-023-32515-6}
}

@article{knopman2023-37295957,
  author  = {Knopman, D. S. and Hershey, L.},
  title   = {{Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?}},
  journal = {Neurology},
  year    = {2023},
  doi     = {10.1212/wnl.0000000000207438},
  pmid    = {37295957},
  url     = {https://doi.org/10.1212/wnl.0000000000207438}
}

@article{cantoni2025-41359335,
  author  = {Cantoni, V. and Casula, E. P. and Tarantino, B. and Cupidi, C. and Huber, N. and Altomare, D. and Premi, E. and Zummo, E. and others},
  title   = {{Home-Based Gamma Transcranial Alternating Current Stimulation in Patients With Alzheimer Disease: A Randomized Clinical Trial}},
  journal = {JAMA network open},
  year    = {2025},
  doi     = {10.1001/jamanetworkopen.2025.46556},
  pmid    = {41359335},
  url     = {https://doi.org/10.1001/jamanetworkopen.2025.46556}
}

@article{barthel2011-21481640,
  author  = {Barthel, H. and Gertz, H. J. and Dresel, S. and Peters, O. and Bartenstein, P. and Buerger, K. and Hiemeyer, F. and Wittemer-Rump, S. M. and others},
  title   = {{Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study}},
  journal = {The Lancet. Neurology},
  year    = {2011},
  doi     = {10.1016/s1474-4422(11)70077-1},
  pmid    = {21481640},
  url     = {https://doi.org/10.1016/s1474-4422(11)70077-1}
}

@article{geldmacher2003-12834513,
  author  = {Geldmacher, D. S. and Provenzano, G. and McRae, T. and Mastey, V. and Ieni, JR.},
  title   = {{Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease}},
  journal = {Journal of the American Geriatrics Society},
  year    = {2003},
  doi     = {10.1046/j.1365-2389.2003.51306.x},
  pmid    = {12834513},
  url     = {https://doi.org/10.1046/j.1365-2389.2003.51306.x}
}

@article{siemers2016-26238576,
  author  = {Siemers, E. R. and Sundell, K. L. and Carlson, C. and Case, M. and Sethuraman, G. and Liu-Seifert, H. and Dowsett, S. A. and Pontecorvo, M. J. and others},
  title   = {{Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2016},
  doi     = {10.1016/j.jalz.2015.06.1893},
  pmid    = {26238576},
  url     = {https://doi.org/10.1016/j.jalz.2015.06.1893}
}

@article{coleman2025-39862881,
  author  = {Coleman, K. K. L. and Berry, S. and Cummings, J. and Hsiung, G. R. and Laforce, R. and Huey, E. and Ducharme, S. and Tartaglia, M. C. and Mendez, M. F. and Onyike, C. and others},
  title   = {{Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial}},
  journal = {The Lancet Neurology},
  year    = {2025},
  doi     = {10.1016/S1474-4422(24)00456-3},
  pmid    = {39862881},
  url     = {https://doi.org/10.1016/S1474-4422(24)00456-3}
}

@article{salloway2011-21917766,
  author  = {Salloway, S. and Sperling, R. and Keren, R. and Porsteinsson, A. P. and van Dyck, C. H. and Tariot, P. N. and Gilman, S. and Arnold, D. and others},
  title   = {{A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2011},
  doi     = {10.1212/wnl.0b013e3182309fa5},
  pmid    = {21917766},
  url     = {https://doi.org/10.1212/wnl.0b013e3182309fa5}
}

@article{rafii2018-29582053,
  author  = {Rafii, M. S. and Tuszynski, M. H. and Thomas, R. G. and Barba, D. and Brewer, J. B. and Rissman, R. A. and Siffert, J. and Aisen, P. S. and others},
  title   = {{Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2018},
  doi     = {10.1001/jamaneurol.2018.0233},
  pmid    = {29582053},
  url     = {https://doi.org/10.1001/jamaneurol.2018.0233}
}

@article{schneider2019-31492718,
  author  = {Schneider, L. S. and Geffen, Y. and Rabinowitz, J. and Thomas, R. G. and Schmidt, R. and Ropele, S. and Weinstock, M. and {Ladostigil Study Group}},
  title   = {{Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial}},
  journal = {Neurology},
  year    = {2019},
  doi     = {10.1212/wnl.0000000000008239},
  pmid    = {31492718},
  url     = {https://doi.org/10.1212/wnl.0000000000008239}
}

@article{saito2023-38048134,
  author  = {Saito, S. and Suzuki, K. and Ohtani, R. and Maki, T. and Kowa, H. and Tachibana, H. and Washida, K. and Kawabata, N. and others},
  title   = {{Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial}},
  journal = {JAMA network open},
  year    = {2023},
  doi     = {10.1001/jamanetworkopen.2023.44938},
  pmid    = {38048134},
  url     = {https://doi.org/10.1001/jamanetworkopen.2023.44938}
}

@article{jeong2022-36038268,
  author  = {Jeong, S. Y. and Suh, C. H. and Shim, W. H. and Lim, J. S. and Lee, J. H. and Kim, S. J.},
  title   = {{Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis}},
  journal = {Neurology},
  year    = {2022},
  doi     = {10.1212/wnl.0000000000201019},
  pmid    = {36038268},
  url     = {https://doi.org/10.1212/wnl.0000000000201019}
}

@article{andreasen2015-25789616,
  author  = {Andreasen, N. and Simeoni, M. and Ostlund, H. and Lisjo, P. I. and Fladby, T. and Loercher, A. E. and Byrne, G. J. and Murray, F. and others},
  title   = {{First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study}},
  journal = {PloS one},
  year    = {2015},
  doi     = {10.1371/journal.pone.0098153},
  pmid    = {25789616},
  url     = {https://doi.org/10.1371/journal.pone.0098153}
}

@article{blennow2012-22473769,
  author  = {Blennow, K. and Zetterberg, H. and Rinne, J. O. and Salloway, S. and Wei, J. and Black, R. and Grundman, M. and Liu, E. and others},
  title   = {{Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease}},
  journal = {Archives of neurology},
  year    = {2012},
  doi     = {10.1001/archneurol.2012.90},
  pmid    = {22473769},
  url     = {https://doi.org/10.1001/archneurol.2012.90}
}

@article{edwards2023-37902726,
  author  = {Edwards, A. L. and Collins, J. A. and Junge, C. and Kordasiewicz, H. and Mignon, L. and Wu, S. and Li, Y. and Lin, L. and others},
  title   = {{Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2023},
  doi     = {10.1001/jamaneurol.2023.3861},
  pmid    = {37902726},
  url     = {https://doi.org/10.1001/jamaneurol.2023.3861}
}

@article{lithell2003-12714861,
  author  = {Lithell, H. and Hansson, L. and Skoog, I. and Elmfeldt, D. and Hofman, A. and Olofsson, B. and Trenkwalder, P. and Zanchetti, A. and others},
  title   = {{The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial}},
  journal = {Journal of hypertension},
  year    = {2003},
  doi     = {10.1097/00004872-200305000-00011},
  pmid    = {12714861},
  url     = {https://doi.org/10.1097/00004872-200305000-00011}
}

@article{sharma2026-41985132,
  author  = {Sharma, Mukul and Dong, Qiang and Hirano, Teruyuki and Kasner, Scott Eric and Saver, Jeffrey L. and Masjuan, Jaime and Demchuk, Andrew M. and Cordonnier, Charlotte and others},
  title   = {{Asundexian for Secondary Stroke Prevention}},
  journal = {New England Journal of Medicine},
  year    = {2026},
  doi     = {10.1056/nejmoa2513880},
  pmid    = {41985132},
  url     = {https://doi.org/10.1056/nejmoa2513880}
}

@article{liu2025-40507855,
  author  = {Liu, X. and Baxley, S. and Hebron, M. and Turner, R. S. and Moussa, C.},
  title   = {{Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer's Disease}},
  journal = {International journal of molecular sciences},
  year    = {2025},
  doi     = {10.3390/ijms26115044},
  pmid    = {40507855},
  url     = {https://doi.org/10.3390/ijms26115044}
}

@article{wessels2018-29616706,
  author  = {Wessels, A M and Andersen, S W and Dowsett, S A and Siemers, E R},
  title   = {{The Integrated Alzheimer's Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2018},
  doi     = {10.14283/jpad.2018.10},
  pmid    = {29616706},
  url     = {https://doi.org/10.14283/jpad.2018.10}
}

@article{kishnani2009-19606472,
  author  = {Kishnani, P. S. and Sommer, B. R. and Handen, B. L. and Seltzer, B. and Capone, G. T. and Spiridigliozzi, G. A. and Heller, J. H. and Richardson, S. and others},
  title   = {{The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome}},
  journal = {American journal of medical genetics. Part A},
  year    = {2009},
  doi     = {10.1002/ajmg.a.32953},
  pmid    = {19606472},
  url     = {https://doi.org/10.1002/ajmg.a.32953}
}

@article{berry2023-37040116,
  author  = {Berry, D. A. and Dhadda, S. and Kanekiyo, M. and Li, D. and Swanson, C. J. and Irizarry, M. and Kramer, L. D. and Berry, S. M.},
  title   = {{Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial}},
  journal = {JAMA network open},
  year    = {2023},
  doi     = {10.1001/jamanetworkopen.2023.7230},
  pmid    = {37040116},
  url     = {https://doi.org/10.1001/jamanetworkopen.2023.7230}
}

@article{humbert2025-40167274,
  author  = {Humbert, Marc and McLaughlin, Vallerie V. and Badesch, David B. and Ghofrani, Hossein Ardeschir and Gibbs, J. Simon R. and Gomberg‐Maitland, Mardi and Preston, Ioana R. and Souza, Rogério and others},
  title   = {{Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death}},
  journal = {New England Journal of Medicine},
  year    = {2025},
  doi     = {10.1056/nejmoa2415160},
  pmid    = {40167274},
  url     = {https://doi.org/10.1056/nejmoa2415160}
}